FIELD NOTE
The new US-China tariff deal names medical devices. The 77-line list of Chinese goods getting relief doesn’t include one.
The White House published the first real output of the U.S.-China Board of Trade on September 27: two product lists under what the administration calls the “30-for-30” framework, roughly $30 billion of goods on each side recommended for more favorable tariff treatment. U.S. Trade Representative Jamieson Greer’s statement led with the sector by name. “From agricultural products to medical devices,” he said, the administration is “unlocking improved market access for about 30 percent of U.S. exports to China.”
Then you read the lists, and the sentence narrows considerably.
The list of Chinese goods recommended for lower U.S. duties runs 77 lines. Fireworks. Plastic tableware. Bed linen and table linen. Garden umbrellas, artificial flowers, electric shavers, microwave ovens, Christmas-tree lamps, highchairs, child safety seats, toys, billiard tables, fish hooks, artists’ brushes, vacuum flasks. Not one line sits in HTS chapter 90, where surgical, diagnostic and measuring instruments are classified. Nothing in heading 3006 or 3822 either — medical consumables and diagnostic reagents. The closest thing to a medical product on the entire list is 84231000: baby scales.
The medtech relief is all on the other side of the ledger. The companion list of U.S. exports that China will consider for lower duties runs about 1,619 lines, and that is where devices appear. Which means the benefit on offer goes to companies shipping American-built devices into China. It does nothing for the much larger set of companies whose exposure runs the other direction — the ones buying Chinese components, subassemblies, injection-molded parts and finished consumables, which is most of the industry.
And it is worth being precise about what “recommended” buys. The terms of reference value both lists by reference to 2024 bilateral trade figures and state that reductions “will be determined and implemented in accordance with each side’s domestic legal processes.” No rates. No effective date. Deputies may propose adjustments to the lists at least annually. There is no enforcement language and no termination clause. This is a standing bilateral committee with a published agenda, which is more than existed in May, and considerably less than a tariff schedule.
Meanwhile the import side of a device company’s cost structure is exactly where it was last week. Section 301 duties on Chinese-origin syringes and needles stand at 100 percent, in force since September 2024. Gloves went to 100 percent and masks and respirators to 50 percent at the start of this year. None of that is on the 77 lines.
The larger thing still sitting open is the Section 232 investigation into imports of personal protective equipment, medical consumables and medical equipment, including devices. Commerce initiated it September 2, 2025 and published the comment notice on September 26, 2025. Its scope is not narrow: masks, gloves, syringes, IV bags, catheters, sutures, wheelchairs, hospital beds, pacemakers, insulin pumps, coronary stents, heart valves, hearing aids, prosthetics. The statutory report was due at the end of May 2026. Four months past that date, no determination has been announced.
Use pharmaceuticals as the clock. That Section 232 opened April 1, 2025, produced a proclamation April 2, 2026, and took effect July 31, 2026 at 100 percent on patented pharmaceutical imports, with a 15 percent tier for the EU, Japan, Korea and Switzerland and a deferral to September 29 for seventeen named companies. Initiation to proclamation ran about twelve months. The device investigation passed that mark a month ago.
So the trade news this week is better read as a sequencing signal than a cost event. Washington has now built a mechanism that can lower tariffs on Chinese consumer goods at an annual cadence, named medtech in the press release for the export-access half of it, and left the half that would actually reduce the landed cost of a device untouched — while keeping a national-security tariff instrument loaded and pointed at the same category. AdvaMed, MDMA and the American Hospital Association all filed against device tariffs last fall. None of them got a decision; they got a trade board.
For anyone modeling 2027 COGS, the practical read is that the downside case on Chinese inputs has not been retired and the upside case on Chinese market access is a recommendation with no number attached. Companies with U.S. manufacturing and a China sales motion have a reason to look at the 1,619-line list for their own codes this week. Everyone else should assume their input costs are a policy decision someone else has not made yet, and should not build a plan that needs that decision to go their way.
SPONSORED BY RŌG HEALTH
Most device companies don’t fail on technology. They fail on sequencing.
The gaps that stall a raise or a hospital deal are usually visible months earlier: an unclear buyer, thin evidence, economics nobody has pressure-tested. They're cheap to fix early and expensive to fix mid-deal.
RŌG Health rebuilt its free Commercial Readiness Check to find them. Seven questions, about two minutes. You get a score out of 15, a profile across five commercial areas showing where you're most exposed, and a read on what to settle first given your next milestone and how soon it is. No pitch at the end. If you want to talk through your answers, you can book a 20-minute call from the results page.
Want to put your brand in front of 28,000+ medical device and med tech leaders each week? Contact us to learn more about advertising opportunities.
🧭 About The Pathway
The Pathway is a curated briefing for medical device leaders, focused on regulatory moves, product launches, partnerships, and market signals shaping the industry.
If this was useful, consider subscribing or sharing with a colleague tracking these developments.
Some issues may include sponsored or partner content. Sponsorship does not influence editorial selection of third-party news items.